Clinical Trial

Serological Autoantibodies in Early Kidney Cancer Diagnosis and Prognosis: A Multicenter Study

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This project aims to construct a multicenter retrospective study by retrospectively collecting clinical, serological, and pathological data from patients. A comprehensive data management system will be established to facilitate the integration and analysis of multicenter data, alongside antibody profiling characteristics. A predictive model based on serological autoantibody profiles will be developed and validated using both internal and external cohorts. This model will predict clinical prognostic factors in renal carcinoma and identify patient populations likely to respond to immunotherapy. By enabling personalized treatment decisions and minimizing unnecessary treatment risks, the model aims to improve patient quality of life and overall prognosis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-01.
Trial Details
NCT Number NCT06917560
Lead Sponsor First Affiliated Hospital of Fujian Medical University
Collaborators: China-Japan Friendship Hospital, The First Affiliated Hospital of Xiamen University
Conditions Renal Carcinoma, Serology, Autoantibody
Enrollment 400 participants
Start Date 2025-04-01
Primary Completion 2027-08-01 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-18